NASDAQ:TLRYTilray Stock Price, Forecast & News

Tilray's stock was trading at $7.09 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, TLRY shares have increased by 39.6% and is now trading at $9.90. View which stocks have been most impacted by Coronavirus.

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tilray in the last year. There are currently 3 sell ratings, 12 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Tilray.

Tilray is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Tilray.

Tilray Inc (NASDAQ:TLRY) announced its quarterly earnings data on Monday, May, 11th. The company reported ($1.73) earnings per share for the quarter, missing the consensus estimate of ($0.44) by $1.29. The business had revenue of $52.20 million for the quarter, compared to analyst estimates of $49.37 million. Tilray had a negative return on equity of 62.82% and a negative net margin of 241.79%. The business's quarterly revenue was up 127.0% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.27) EPS. View Tilray's earnings history.

17 Wall Street analysts have issued 1 year target prices for Tilray's shares. Their forecasts range from $4.00 to $54.00. On average, they anticipate Tilray's share price to reach $17.88 in the next year. This suggests a possible upside of 80.7% from the stock's current price. View analysts' price targets for Tilray.

News articles about TLRY stock have trended extremely negative on Friday, InfoTrie reports. InfoTrie rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Tilray earned a news impact score of -4.8 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutTilray.

Tilray saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 16,520,000 shares, an increase of 7.8% from the March 31st total of 15,330,000 shares. Based on an average trading volume of 9,370,000 shares, the days-to-cover ratio is presently 1.8 days. Currently, 21.2% of the company's shares are short sold. View Tilray's Current Options Chain.

Some companies that are related to Tilray include STADA Arzneimittel (STDAF), Cronos Group (CRON), USANA Health Sciences (USNA), Aurora Cannabis (ACB), Aphria (APHA), Canopy Rivers (RIV), Chromadex (CDXC), Sundial Growers (SNDL), Happiness Biotech Group (HAPP), Mediwound (MDWD), Natural Alternatives International (NAII), Mannatech (MTEX), Cyanotech (CYAN), True Drinks (TRUU) and FitLife Brands (FTLF). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Tilray investors own include Canopy Growth (CGC), Cronos Group (CRON), Aurora Cannabis (ACB), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Netflix (NFLX), Advanced Micro Devices (AMD), Aphria (APHA) and Square (SQ).

(TLRY) raised $135 million in an initial public offering (IPO) on Thursday, July 19th 2018. The company issued 9,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Company served as the underwriter for the IPO and Roth Capital Partners and Northland Securities were co-managers.

Tilray trades on the NASDAQ under the ticker symbol "TLRY."

Tilray's stock is owned by many different retail and institutional investors. Top institutional shareholders include ETF Managers Group LLC (2.47%), CIBC World Markets Inc. (0.16%), Hellman Jordan Management Co. Inc. MA (0.08%), Advisor Group Holdings Inc. (0.08%), Geode Capital Management LLC (0.05%) and Stelac Advisory Services LLC (0.06%). Company insiders that own Tilray stock include Brendan Kennedy, Christine StClare, Edward Wood Pastorius Jr, Mark Castaneda and Michael Auerbach. View institutional ownership trends for Tilray.

TLRY stock was sold by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, Commerzbank Aktiengesellschaft FI, AdvisorShares Investments LLC, BNP Paribas Arbitrage SA, Stelac Advisory Services LLC, and Exane Derivatives. Company insiders that have sold Tilray company stock in the last year include Brendan Kennedy, Christine StClare, and Michael Auerbach. View insider buying and selling activity for Tilray.

TLRY stock was purchased by a variety of institutional investors in the last quarter, including ETF Managers Group LLC, CIBC World Markets Inc., Hellman Jordan Management Co. Inc. MA, Advisor Group Holdings Inc., Thrivent Financial for Lutherans, UBS Group AG, Cambridge Investment Research Advisors Inc., and Two Sigma Advisers LP. Company insiders that have bought Tilray stock in the last two years include Brendan Kennedy, and Edward Wood Pastorius Jr. View insider buying and selling activity for Tilray.

Shares of TLRY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of TLRY stock can currently be purchased for approximately $9.90.

Tilray has a market capitalization of $1.23 billion and generates $166.98 million in revenue each year. The company earns $-321,170,000.00 in net income (profit) each year or ($1.69) on an earnings per share basis. Tilray employs 1,646 workers across the globe.

The official website for Tilray is www.tilray.com.

Tilray's mailing address is 1100 MAUGHAN ROAD, NANAIMO A1, V9X 1J2. The company can be reached via phone at 206-432-9325.